Class summary at a glance.

Every drug in the Phosphate Binder class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 3tracked in Part D
CY24 Part D spend: $645.2Mcombined across class
Total Rx claims: 1.0M271K unique beneficiaries
Generic mfrs (active): 21across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Sucroferric Oxyhydroxide

Brand: Velphoro · 157K Part D claims (CY24) · 39K beneficiaries · First FDA approval: 2013-11-27

Brand-only (no generics)

Low NADAC$17.11

→

Avg plan cost$17.11

Part D spend $439.3M 1× spread, current vs floor

Class share

68%

of class CY24 spend

View profile →

Sevelamer Carbonate

Brand: Renvela · 815K Part D claims (CY24) · 220K beneficiaries · First FDA approval: 2009-08-12

16 generic mfrs

Low NADAC$0.214

→

Avg plan cost$1.16

Part D spend $181.9M 5× spread, current vs floor

Class share

28%

of class CY24 spend

View profile →

Sevelamer

38K Part D claims (CY24) · 13K beneficiaries · First FDA approval: 2019-02-08

5 generic mfrs

Low NADAC$0.856

→

Avg plan cost$1.03

Part D spend $24.0M 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.